Acorda Therapeutics Inc (NASDAQ:ACOR) has been assigned a consensus rating of “Hold” from the seventeen brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $25.64.
ACOR has been the topic of several recent research reports. HC Wainwright set a $31.00 price target on shares of Acorda Therapeutics and gave the company a “buy” rating in a research report on Wednesday, May 30th. BidaskClub upgraded shares of Acorda Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, June 1st. ValuEngine upgraded shares of Acorda Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, June 8th. Oppenheimer set a $21.00 price objective on shares of Acorda Therapeutics and gave the company a “hold” rating in a report on Monday, June 11th. Finally, TheStreet upgraded shares of Acorda Therapeutics from a “d+” rating to a “c-” rating in a report on Tuesday, June 19th.
Shares of ACOR stock traded down $0.25 on Monday, hitting $27.55. 233,223 shares of the stock traded hands, compared to its average volume of 328,411. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.56. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of 26.49 and a beta of 1.46. Acorda Therapeutics has a twelve month low of $16.55 and a twelve month high of $36.35.
Acorda Therapeutics (NASDAQ:ACOR) last announced its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.90. The firm had revenue of $153.30 million for the quarter, compared to analysts’ expectations of $138.63 million. Acorda Therapeutics had a negative net margin of 26.87% and a positive return on equity of 8.19%. The company’s revenue was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.29 EPS. equities research analysts predict that Acorda Therapeutics will post -0.09 EPS for the current year.
In other Acorda Therapeutics news, major shareholder Scopia Capital Management Lp sold 167,773 shares of the business’s stock in a transaction dated Tuesday, June 12th. The shares were sold at an average price of $31.27, for a total transaction of $5,246,261.71. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider David Lawrence sold 3,431 shares of the business’s stock in a transaction dated Tuesday, June 12th. The stock was sold at an average price of $31.74, for a total transaction of $108,899.94. Following the sale, the insider now owns 4,993 shares in the company, valued at $158,477.82. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,283,648 shares of company stock worth $39,101,584. 7.80% of the stock is owned by insiders.
Large investors have recently modified their holdings of the business. Massachusetts Financial Services Co. MA increased its stake in Acorda Therapeutics by 15.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 57,010 shares of the biopharmaceutical company’s stock worth $1,637,000 after purchasing an additional 7,811 shares during the period. Rhumbline Advisers increased its stake in Acorda Therapeutics by 2.1% during the first quarter. Rhumbline Advisers now owns 110,279 shares of the biopharmaceutical company’s stock worth $2,608,000 after purchasing an additional 2,268 shares during the period. Whittier Trust Co. increased its stake in Acorda Therapeutics by 13,004.4% during the second quarter. Whittier Trust Co. now owns 32,761 shares of the biopharmaceutical company’s stock worth $1,104,000 after purchasing an additional 32,511 shares during the period. GSA Capital Partners LLP purchased a new stake in Acorda Therapeutics during the first quarter worth about $1,984,000. Finally, Crossmark Global Holdings Inc. purchased a new stake in Acorda Therapeutics during the second quarter worth about $229,000.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.
Read More: Marijuana Stocks Investing Considerations
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.